Madam Therapeutics is an innovative biotech company that develops novel antimicrobial therapies to replace the failing traditional antibiotics and combat the global challenge of antimicrobial resistance (AMR). We do this by leveraging a revolutionary technology inspired on the body’s own natural human defense peptides against bacteria using Artificial Intelligence models. We are now looking for financing to bring our abundant pipeline of compounds into the clinic.

Madam Therapeutics is currently raising a €10M series A funding for the development of at least 1 compound up to clinical phase I proof of concept and the development of 2 compounds up to in vivo proof of concept. After the phase I/IIa clinical study, Madam Therapeutics aims to out-license the product(s) to a larger a pharma company for further development and commercialisation.
Read more about Madam Therapeutics.